JanOne Surges 50% On Issuance Of U.S. Patent Covering Method Of Improving Nerve Function Using JAN10

Shares of nano-cap company JanOne Inc. (JAN) gained nearly 50% on Tuesday morning after the company announced the issuance of U.S. Patent Covering a method of improving nerve function using JAN101.

JAN is currently trading at $3.71, up $1.21 or 48.40% on the NASDAQ, on a heavy volume of 51 million shares, above average volume of 0.6 million. The stock opened its trading at $3.55 after closing Monday's trading at $2.50. The stock has traded between $1.89 and $12.28 in the past 52-week period.

JanOne said that a patent was issued that covers a method of improving nerve function using JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT